SLC22A3 and metastatic prostate carcinoma: Indeed, the TCGA [27] and other datasets [28] demonstrated that SLC22A3 is downregulated in tumor tissue samples compared with normal compartments (Figure 1A–C), and it is significantly diminished in castration-resistant metastatic prostate cancers [29,30].